According to MannKind Corporation, it remains committed to gaining approval for its Afrezza inhaled insulin despite continuing requests from the FDA for additional data. The company announced that it is restructuring in order to focus on the Afrezza approval, resulting in a layoff of 41% of its workforce. MannKind’s net loss for 2010 was more than $170 million. Read the company’s press release.
Mannkind cuts more than 40% of workforce
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
